Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes

References

• International Diabetes Foundation. Diabetes Atlas [7th edition] 2015. Available at: http://www.diabetesatlas.org/
   Google Scholar
• Centers for Disease Control and Prevention. National Diabetes Statistics Report 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
   Google Scholar
• Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35
   PubMed Web of Science ®Google Scholar
• Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 2016;316:602-10
   PubMed Web of Science ®Google Scholar
• Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014;7:415
   PubMedGoogle Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-52
   PubMed Web of Science ®Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8
   PubMed Web of Science ®Google Scholar
• Baba M, Shimbo T, Horio M, et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS One 2015;10:e0129036
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Trevisan R, Vedovato M, Mazzon C, et al. Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients. Diabetes Care 2002;25:2026-31
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-5
   PubMed Web of Science ®Google Scholar
• Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990;33:438-43
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
   PubMed Web of Science ®Google Scholar
• Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes 2014;32:4-11
   PubMedGoogle Scholar
• Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8
   PubMed Web of Science ®Google Scholar
• Wells RG, Pajor AM, Kanai Y, et al. Cloning of a human kidney cDNA with similarity to the sodium–glucose cotransporter. Am J Physiol 1992;263(3 Pt 2):F459-65
   PubMedGoogle Scholar
• You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995;270:29365-71
   PubMed Web of Science ®Google Scholar
• Triplitt CL. Understanding the kidneys’ role in blood glucose regulation. Am J Manag Care 2012;18(1Suppl):S11-S16
   Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34
   PubMed Web of Science ®Google Scholar
• Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008;82(Suppl1):S75-S9
   Google Scholar
• Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998;102:619-24
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004;15(Suppl1):S55-S7
   Google Scholar
• Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007;106:26-31
   Web of Science ®Google Scholar
• Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626-34
   PubMed Web of Science ®Google Scholar
• Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352(9123):213-19
   PubMed Web of Science ®Google Scholar
• Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42
   PubMed Web of Science ®Google Scholar
• Singh AK, Mo W, Dunea G, Arruda JA. Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 1998;9:802-10
   PubMed Web of Science ®Google Scholar
• Hoogwerf BJ. Renin–angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010;105(1Suppl):30-5A
   Google Scholar
• Microalbuminuria Collaborative Study Group. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 1993;306:1235-9
   PubMedGoogle Scholar
• Pecis M, Azevedo MJ, Gross JL. Glomerular hyperfiltration is associated with blood pressure abnormalities in normotensive normoalbuminuric IDDM patients. Diabetes Care 1997;20:1329-33
   PubMed Web of Science ®Google Scholar
• Gillespie CD, Hurvitz KA, Centers for Disease Control and Prevention. Prevalence of hypertension and controlled hypertension – United States, 2007–2010. MMWR Suppl 2013;62:144-8
   PubMedGoogle Scholar
• Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010;53:2093-104
   PubMed Web of Science ®Google Scholar
• Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012;8:293-300
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium–glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97
   PubMed Web of Science ®Google Scholar
• Schnaper HW. Remnant nephron physiology and the progression of chronic kidney disease. Pediatr Nephrol 2014;29:193-202
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012;35:2061-8
   PubMed Web of Science ®Google Scholar
• von Mering J. Ueber kunstlichen diabetes. Centralbl Med Wiss 1885;23:531
   Google Scholar
• Chasis H, Jolliffe N, Smith HW. The Action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 1933;12:1083-90
   PubMedGoogle Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83-90
   PubMed Web of Science ®Google Scholar
• Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc. Invokana (canagliflozin) tablets, for oral use 2016. Available at: https://www.invokanahcp.com/sites/www.invokanahcp.com/files/prescribing-information-invokana.pdf
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Jardiance (empagliflozin) tables, for oral use [prescribing information] 2016. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
   Google Scholar
• AstraZeneca Pharmaceuticals LP. Farxiga (dapagliflozin) tablets, for oral use [prescribing information] 2016. Available at: http://www.azpicentral.com/farxiga/pi_farxiga.pdf
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Chuck L, Gonzalez-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 2016;39:353-62
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
   PubMed Web of Science ®Google Scholar
• Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19
   PubMed Web of Science ®Google Scholar
• Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9
   PubMed Web of Science ®Google Scholar
• Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6
   PubMed Web of Science ®Google Scholar
• Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:235-51
   PubMed Web of Science ®Google Scholar
• Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17:1695-702
   PubMed Web of Science ®Google Scholar
• Jonk AM, Houben AJ, de Jongh RT, et al. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 2007;22:252-60
   PubMed Web of Science ®Google Scholar
• Serne EH, de Jongh RT, Eringa EC, et al. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007;50:204-11
   PubMed Web of Science ®Google Scholar
• Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology 2008;15:79-89
   PubMedGoogle Scholar
• Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011;6:2364-73
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008;73:19-33
   PubMed Web of Science ®Google Scholar
• Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 2004;11:41-54
   PubMedGoogle Scholar
• Ruster C, Wolf G. The role of the renin–angiotensin–aldosterone system in obesity-related renal diseases. Semin Nephrol 2013;33:44-53
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Corradi L, et al. Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. Hypertens Res 2010;33:236-42
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:1565-74
   PubMed Web of Science ®Google Scholar
• Blonde L, Stenlof K, Fung A, et al. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 2016;128:371-80
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cain V, Rohwdder J, Johnsson E. Maintenance of weight loss with dapagliflozin vs. glipizide as add-on to metformin over 4 years. Presented at: American Diabetes Association (ADA) 75th Scientific Sessions, Boston, MA, USA, 2015:103-OR
   Google Scholar
• Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol 2015;14:154
   PubMed Web of Science ®Google Scholar
• Botdorf J, Chaudhary K, Whaley-Connell A. Hypertension in cardiovascular and kidney disease. Cardiorenal Med 2011;1:183-92
   PubMed Web of Science ®Google Scholar
• Segura J, Ruilope LM. Hypertension in moderate-to-severe nondiabetic CKD patients. Adv Chronic Kidney Dis 2011;18:23-7
   PubMed Web of Science ®Google Scholar
• Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-10
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Rennke HG, Salant DJ, et al. Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res 1987;61:531-8
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005;142:342-51
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52
   PubMed Web of Science ®Google Scholar
• International Society of Nephrology. Kidney Disease: Improving Global Outcomes (KDIGO) 2012 clinical practice guideline for the evaluation and management of chronic kidney disesase. Kidney Int Suppl 2013;3:1-150
   Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74
   PubMed Web of Science ®Google Scholar
• Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330-9
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. Forxiga summary of product characteristics 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf
   Google Scholar
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:1180-93
   PubMed Web of Science ®Google Scholar
• Mancia G, Cannon CP, Tikkanen I, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 2016;68:1355-64
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56
   PubMed Web of Science ®Google Scholar
• Abbate M, Benigni A, Bertani T, Remuzzi G. Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999;14:304-12
   PubMed Web of Science ®Google Scholar
• Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003;41:588-95
   PubMed Web of Science ®Google Scholar
• Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 2014;37:867-75
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin–angiotensin blockers. Diabetes Obes Metab 2016;18:590-7
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Kurlyandskaya RJX, Sjostrom CD. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. 76th Scientific Sessions of the American Diabetes Association, New Orleans, LA, USA, 2016:1095-P
   Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-84
   PubMed Web of Science ®Google Scholar
• Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013;61:134-46
   PubMed Web of Science ®Google Scholar
• Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009;169:342-50
   PubMed Web of Science ®Google Scholar
• Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Curr Rheumatol Rep 2007;9:251-7
   PubMedGoogle Scholar
• Curhan GC. Epidemiology of stone disease. Urol Clin North Am 2007;34:287-93
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-7
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-47
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7
   PubMed Web of Science ®Google Scholar
• Coe FL. Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983;24:392-403
   PubMed Web of Science ®Google Scholar
• Rieselbach RE, Steele TH. Influence of the kidney upon urate homeostasis in health and disease. Am J Med 1974;56:665-75
   PubMed Web of Science ®Google Scholar
• Whitehead TP, Jungner I, Robinson D, et al. Serum urate, serum glucose and diabetes. Ann Clin Biochem 1992;29(Pt 2):159-61
   PubMed Web of Science ®Google Scholar
• Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986;62:1001-6
   PubMed Web of Science ®Google Scholar
• Skeith MD, Healey LA, Cutler RE. Effect of phloridzin on uric acid excretion in man. Am J Physiol 1970;219:1080-2
   PubMed Web of Science ®Google Scholar
• Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol 1997;10:188-91
   PubMed Web of Science ®Google Scholar
• Mende C. Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy. Adv Ther 2015;32:1177-91
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014;35:391-404
   PubMed Web of Science ®Google Scholar
• Davies MJ, Trujillo A, Vijapurkar U, et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:426-9
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
   PubMed Web of Science ®Google Scholar
• Pham PC, Pham PM, Pham SV, et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007;2:366-73
   PubMed Web of Science ®Google Scholar
• Pham PC, Pham PM, Pham PT, et al. The link between lower serum magnesium and kidney function in patients with diabetes mellitus type 2 deserves a closer look. Clin Nephrol 2009;71:375-9
   PubMed Web of Science ®Google Scholar
• Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes 2016;65:3-13
   PubMed Web of Science ®Google Scholar
• Pham PC, Pham PM, Pham PA, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005;63:429-36
   PubMed Web of Science ®Google Scholar
• Van Laecke S, Nagler EV, Verbeke F, et al. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013;126:825-31
   PubMed Web of Science ®Google Scholar
• Barbagallo M, Dominguez LJ. Magnesium and type 2 diabetes. World J Diabetes 2015;6:1152-7
   PubMed Web of Science ®Google Scholar
• Rodriguez-Moran M, Simental Mendia LE, Zambrano Galvan G, Guerrero-Romero F. The role of magnesium in type 2 diabetes: a brief based-clinical review. Magnes Res 2011;24:156-62
   PubMed Web of Science ®Google Scholar
• Spiegel DM. Magnesium in chronic kidney disease: unanswered questions. Blood Purif 2011;31:172-6
   PubMed Web of Science ®Google Scholar
• Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014;30:1759-68
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Mende C, Vijapurkar U, et al. Effects of canagliflozin (CANA) on serum magnesium (Mg) in patients with type 2 diabetes mellitus (T2DM). 76th Scientific Sessions of the American Diabetes Association. New Orleans, LA, USA, 2016:129-LB
   Google Scholar
• List JF, Woo V, Morales E, et al. Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 2016;59:2546-51
   PubMed Web of Science ®Google Scholar
• Shiga T, Wajima Z, Inoue T, Ogawa R. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Med 2004;117:325-33
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71
   PubMed Web of Science ®Google Scholar
• Gilbert RE. SGLT-2 inhibition in patients with kidney disease. Diabetes Metab 2014;40(6Suppl1):S23-S7
   Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin (CANA) slows progression of renal function decline independent of glycemic effects. Presented at: 76th Scientific Sessions of the American Diabetes Association. New Orleans, LA, USA, 2016:70-OR
   Google Scholar
• Kohan DE, Fioretto P, Johnsson K, et al. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016;29:391-400
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) 2016. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm
   Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34
   PubMed Web of Science ®Google Scholar
• Skrtic M, Cherney DZ. Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015;24:96-103
   PubMed Web of Science ®Google Scholar
• Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:1087-95
   PubMed Web of Science ®Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:613-21
   PubMed Web of Science ®Google Scholar
• Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
   PubMed Web of Science ®Google Scholar
• Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999;42:920-5
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015;3:8-10
   PubMed Web of Science ®Google Scholar
• Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 2016;18:1199-1206
   PubMed Web of Science ®Google Scholar
• Jensen LB, Quaade F, Sorensen OH. Bone loss accompanying voluntary weight loss in obese humans. J Bone Miner Res 1994;9:459-63
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res 2012;27:619-27
   PubMed Web of Science ®Google Scholar
• Alba M, Xie J, Fung A, Desai M. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 2016;32:1375-8
   PubMed Web of Science ®Google Scholar
• Hinton PS, LeCheminant JD, Smith BK, et al. Weight loss-induced alterations in serum markers of bone turnover persist during weight maintenance in obese men and women. J Am Coll Nutr 2009;28:565-73
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157-66
   PubMed Web of Science ®Google Scholar
• Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012;26:501-5
   PubMed Web of Science ®Google Scholar
• Hirji I, Guo Z, Andersson SW, et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications 2012;26:513-16
   PubMed Web of Science ®Google Scholar
• Arakaki RF. Sodium–glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med 2016;128:409-17
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2016: summary of revisions. Diabetes Care 2016;39(Suppl1):S4-S5
   Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006;20:101-8
   PubMed Web of Science ®Google Scholar
• Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016;4:211-20
   PubMed Web of Science ®Google Scholar